Stephens Analyst Earlier Commented On Downside In Repligen Shares: Classifies GE Healthcare's Protein A Resin As 'Niche,' Doesn't See Driving Material Sales For At Least 5 Years; Says Repligen's Sales From GE Will Not Be Impacted, Cites Long-Term Contract
Paul Quintaro